Manosil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Manosil

Property Description
Active Ingredient Metoclopramide Hydrochloride
Pharmacological Class Prokinetic Agent and Dopamine D2 Antagonist
Form Tablet, Oral Solution, Injection
Common Use General relief of nausea and vomiting, restoring gut motility
Origin Synthetic Benzamide Derivative

What Type of Medicine is Manosil (Metoclopramide)?

Manosil is a specialized, prescription-only medication primarily defined by its active component, Metoclopramide, which is officially classified as a dopamine-2 (D2) antagonist. Functionally, the drug is categorized as both a Prokinetic Agent and an Antiemetic. This unique dual designation is significant because the medicine is a synthetic benzamide derivative that acts on both the central nervous system and the gastrointestinal tract. Metoclopramide is recognized for its ability to quickly interrupt central signals that trigger the sickness reflex, distinguishing its profile from agents that focus exclusively on a single mechanism.

Composition and Available Forms of Manosil

Manosil is defined by its active ingredient, Metoclopramide Hydrochloride. This core compound is formulated into several primary dosage forms to accommodate varying needs and the required speed of action. Manosil is available for the oral route of administration as conventional tablets and an oral solution (liquid). Furthermore, for situations requiring rapid therapeutic effect, it is manufactured as an injection for parenteral (intravenous or intramuscular) use. These different forms ensure the product can be administered effectively, particularly when patients require assistance with motility issues.

The General Purpose of This Prokinetic Agent

Manosil is generally purposed to relieve the sensations of nausea and vomiting and to promote motility in the upper gastrointestinal tract. Its ability to stimulate gut movement increases the tone and amplitude of gastric contractions, thereby accelerating the transit of food from the stomach into the intestine. This prokinetic action is instrumental in addressing the underlying issue of slow gastric emptying, while the medicine's antiemetic effect works to calm the central reflex that triggers sickness. The combined effect of restoring upper gut function and controlling nausea is the fundamental benefit provided by this class of drug.

What side effects are possible with Manosil?

Possible Side Effects and Safety Information

The official safety profile of Manosil (Metoclopramide) is rigorously defined by regulatory agencies, with particular emphasis on neurological adverse reactions and duration limitations. The risk of Tardive Dyskinesia (TD), a potentially irreversible movement disorder, is a primary concern and increases with the duration of treatment. For this reason, the treatment duration should not exceed 12 weeks as mandated in official labeling.

Adverse Reaction Classification

Classification Examples of Reactions (Official Labeling)
Very Common (mathbf> 1/10) Drowsiness, fatigue, lassitude, restlessness.
Common (mathbf1/100 to mathbf1/10) Diarrhea, depression, extrapyramidal symptoms, hypotension.
Rare/Not Known Convulsion, Neuroleptic Malignant Syndrome (NMS), cardiac arrest, methemoglobinemia.

Adverse effects are documented across several System-Organ Classes, chiefly Nervous System Disorders (e.g., acute dystonia, Parkinsonism, akathisia), Gastrointestinal Disorders ( diarrhea), and Endocrine Disorders ( hyperprolactinemia-related effects, such as amenorrhea). Acute extrapyramidal reactions may occur at the beginning of treatment or following a single administration, and are generally more frequent in children and young adults.

Serious Safety Constraints

Regulatory documents highlight several serious adverse reactions, including the potentially fatal Neuroleptic Malignant Syndrome (NMS) and severe Cardiovascular Undesirable Effects ( cardiac arrest, circulatory collapse) associated with rapid intravenous administration. The label explicitly contraindicates Manosil in individuals with conditions where stimulating gut motility may be harmful ( gastrointestinal hemorrhage, obstruction, or perforation), as well as in those with Parkinson's disease, epilepsy, or pheochromocytoma.

Overdose and Emergency Response

The official regulatory documents for Manosil (Metoclopramide) define the overdose profile primarily by its documented neurological and systemic toxicity. Manifestations of overdosage include a cluster of Central Nervous System effects such as severe drowsiness, disorientation, confusion, seizures, lethargy, and uncontrolled muscle movements known as Extrapyramidal Reactions (EPS). Gastrointestinal effects like diarrhea are also reported in overexposure situations.

Overdose carries the risk of severe, life-threatening outcomes, including Neuroleptic Malignant Syndrome (NMS), cardiac arrest, and circulatory collapse, particularly after intravenous administration. Immediate medical help must be sought if severe symptoms occur, such as collapse, breathing difficulties, unresponsiveness, or the onset of NMS or EPS; in these cases, the medication must be discontinued immediately as mandated by regulatory bodies.

Management is focused on supportive and symptomatic treatment. To control Extrapyramidal Reactions, anticholinergic or antiparkinson drugs may be administered. Methemoglobinemia, a documented risk particularly in neonates following overdose, can be reversed by the intravenous use of Methylene Blue. Regulatory documentation states that general overdose symptoms are typically self-limiting and may disappear within 24 hours, and notes that dialysis is not a likely effective method for drug removal.

Therapeutic Uses of Manosil

What Manosil Treats: Main Uses and Benefits

Manosil offers supportive therapeutic benefit and is considered relevant for easing symptoms across key domains. The medication’s role includes addressing symptoms associated with acute or episodic changes, which can include symptoms related to heightened physiological activity. It is relevant in contexts marked by increased discomfort or tension and supports the management of symptoms that create noticeable interference with daily functioning.

This medication is commonly used across conditions characterized by episodic or fluctuating manifestations. It helps address symptom clusters that may appear suddenly or intensify over time, contributing to improved day-to-day comfort during periods of heightened symptoms. It is applied across domains where additional symptomatic support is needed, and offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Supportive Role in Managing Discomfort

Manosil is commonly used when short-term symptomatic assistance is needed, especially in situations where symptoms interfere with daily functioning. It contributes to easing the overall symptom load during periods of heightened symptoms.

Eligibility and Restrictions for Use

Manosil (Metoclopramide) is subject to strict eligibility rules defined by regulatory bodies, with use permitted only in specific patient populations under defined circumstances.

Contraindications: Who Must Not Use Manosil

Manosil is contraindicated and must not be used in several patient groups. These absolute exclusions include children under one year of age, patients with a history of tardive dyskinesia, epilepsy or seizure disorders, and patients with Parkinson’s disease. Use is also strictly prohibited in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation, as well as in patients with a known or suspected pheochromocytoma.

Age and Condition-Based Restrictions

Eligibility for use is limited by age and physiological status. Use in children and adolescents (aged 1–18 years) is highly restricted and typically reserved for specific second-line treatments. Older adults may require a mandatory dose reduction due to increased sensitivity and potential age-related organ changes.

Mandatory dose limitations are required for patients with impaired organ function. A significant dose reduction (50% to 75%) is necessary for those with moderate to severe renal impairment or severe hepatic impairment. Furthermore, the maximum duration of treatment is strictly limited (e.g., 5 days or 12 weeks), regardless of the patient population, to maintain eligibility and mitigate cumulative risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Manosil’s interaction profile is officially defined by pharmacodynamic reinforcement and metabolic pathway involvement, as documented in government regulatory labeling.

Contraindicated and Restricted Combinations

The co-administration of Manosil with Dopaminergic Agonists (e.g., Levodopa) is formally contraindicated by regulatory agencies due to their documented mutually antagonistic effects. Official documentation requires avoiding combination with CNS Depressants (such as opioids or benzodiazepines) and other Antipsychotics due to a clear additive pharmacodynamic effect. This effect significantly increases the risk of severe sedation and serious neurological disorders, including Extrapyramidal Symptoms (EPS) and Neuroleptic Malignant Syndrome (NMS). The use of Monoamine Oxidase Inhibitors (MAOIs) is also restricted due to the potential for a hypertensive reaction.

Pharmacokinetic and Absorption Alterations

Manosil is primarily a CYP2D6 substrate. Consequently, co-administration with strong CYP2D6 inhibitors (e.g., fluoxetine, quinidine) is a documented pharmacokinetic interaction that leads to a substantial increase in Manosil's systemic exposure (plasma concentration). Furthermore, Manosil can alter the gastrointestinal absorption of other medicines, officially documented as decreasing the absorption of Digoxin and increasing the absorption of certain analgesics.

Population-Specific Constraints

Regulatory documents require that the potential for drug accumulation be taken into account in specific patient groups. This includes individuals with renal impairment or severe hepatic impairment, where Manosil's clearance is officially reduced. The labeling notes that consideration for dosage adjustments is required in these populations due to the heightened risk of adverse interactions resulting from increased exposure.

Mechanism of Action

How Manosil Works: Pharmacodynamics

Manosil exerts its pharmacodynamic action through three distinct mechanistic domains. The drug's active metabolite acts as an opener of the ATP-sensitive inward rectifier potassium channel 1 (KATP channel), primarily expressed in vascular smooth muscle. This interaction triggers K^+ efflux, causing membrane hyperpolarization and subsequent inhibition of calcium ion influx. The resulting molecular cascade establishes arteriolar vasodilation and a reduction in peripheral vascular resistance.

Locally, Manosil engages intracellular signaling pathways, activating the Extracellular signal-regulated kinase (ERK) and Akt pathways in dermal papillary cells. This modulation of anti-apoptotic proteins and cell proliferation signals alters the phase kinetics of the hair follicle cycle, decreasing the duration of the telogen phase and extending the anagen phase, thus influencing follicle morphology.

Separately, Manosil functions as a physical-chemical osmotic agent. It is freely filtered by the glomerulus and is poorly reabsorbed by the renal tubules, establishing an osmotic gradient. This gradient promotes enhanced water excretion, leading to increased diuresis and subsequent modification of systemic volume and fluid dynamics.

Dosage and Administration Information

How Manosil is Used: Official Dosing and Administration

Manosil (Metoclopramide) is administered according to strict guidelines. These instructions govern the route, dose, frequency, and duration of use.

Approved Routes and Dosage Forms

Manosil is available for the oral route as tablets (typically 10 mg strength) and an oral solution. For immediate or in-patient use, it is available as an injection for intravenous (IV) or intramuscular (IM) administration. When administered intravenously, the dose must be given slowly over a minimum of 1 to 3 minutes, as specified in the labeling.

Standard Adult Dosing and Time Limits

Treatment with Manosil is intended for short-term use only, with clear maximum duration limits.

Use Context Standard Dose Administration Schedule Maximum Duration Limit
Diabetic Gastroparesis (Oral) 10 mg Up to four times daily 12 weeks
Acute Nausea/Vomiting (Oral/Parenteral) 10 mg Up to three times daily 5 days

For oral administration, the drug is typically taken 30 minutes before meals and at bedtime for continuous therapy. A minimal interval of 6 hours between two administrations must be strictly observed, regardless of whether a dose was rejected, to prevent potential accumulation.

Population-Specific Use

Dose modifications are required for specific populations. For patients with severe renal or hepatic impairment, the dosage must be reduced by 50% to account for slower drug clearance. Dose reductions are also recommended for older adults based on a review of their overall function and for individuals identified as CYP2D6 poor metabolizers.

Recent Clinical Evidence

Research evidence / Overview of studies for Manosil

Evidence for Acute Relief of Nausea and Vomiting

Research exploring short-term symptom changes focused on studies evaluating Manosil (Metoclopramide) in contexts such as post-operative conditions and delayed chemotherapy effects. These research efforts primarily examined patient-reported outcomes describing perceived discomfort, focusing on the observation of nausea severity and the number of vomiting episodes over very short time intervals (typically 24 to 48 hours). Studies monitored the administration of rescue anti-sickness medication shortly after the intervention.

However, certainty remains low regarding the effects of using this medicine beyond a very limited duration. Long-term outcomes are not fully established due to safety concerns that restrict the duration of treatment and observation, meaning evidence is limited regarding its role in long-term or chronic management.

Evidence for Use in Stimulating Gut Motility (Diabetic Gastroparesis)

Manosil was studied for conditions marked by functional limitations, specifically the delayed emptying of the stomach in adults with diabetes. Research included comparisons to placebo and monitored outcomes related to systemic imbalance by measuring objective results, such as the rate of stomach emptying, alongside patient-reported outcomes describing perceived discomfort. Findings described patterns observed in the studies related to temporary observations of symptom scores.

Findings were mixed when comparing patient symptom reports against the objective measurements of gastric emptying; research documented that these two outcome axes did not always align. Due to regulatory limits, the results apply only to the very short-term populations studied and do not offer insight into chronic management.

The Study of Acute Migraine-Associated Nausea

The use of Manosil has been evaluated in settings with varying symptom burdens, specifically for individuals experiencing severe acute migraine attacks that often include nausea and vomiting. Research explored the association between administration (often via injection) and the changes measured in both headache pain and the associated nausea. The evidence is limited to this acute, episodic setting, and data related to the oral form in this specific acute scenario are more limited. The evidence does not address the use of the medicine for preventive migraine treatment.

Areas of Uncertainty and Research Gaps

Data for certain special groups, including children (aged 1 and older) and older adults, remain insufficient or require specific attention to study parameters. The primary gap across all indications is the absence of data that addresses the chronic use of the medicine for any condition.

Frequently Asked Questions (FAQ)

Common questions about Manosil (FAQ)


Q: How is Manosil different from other medicines that treat the same condition?

Official product information states that Manosil is classified as having a dual mechanism: it is both a Prokinetic Agent and a Dopamine D2 Antagonist. This means it stimulates gut movement while also blocking signals in the central nervous system that cause sickness. This dual classification defines its distinct mechanism of action.


Q: Does Manosil cure the condition, or does it only manage the symptoms?

Official product information emphasizes that Manosil is intended for symptom management and short-term use, with clear maximum duration limits defined by regulatory authorities (e.g., 12 weeks). The medicine is not studied or intended for curative long-term treatment.


Q: How long after starting Manosil should a person expect to feel a difference?

According to clinical data, the onset of pharmacological effect is typically observed within 30 to 60 minutes following an oral dose. This initial effect generally lasts for about one to two hours.


Q: Is it normal to feel a specific minor side effect when starting Manosil?

Common side effects, such as drowsiness or fatigue, have been frequently reported, especially when treatment is initiated. Less common, but serious, neurological reactions known as Extrapyramidal Symptoms (EPS) may also occur very early in treatment, and are generally more frequent in younger adults.


Q: Can Manosil be taken safely with over-the-counter pain relievers?

Regulatory documents note that Manosil can affect the way the body processes other medicines, and it is specifically documented to increase the absorption of certain analgesics (pain relievers). Official guidance recommends consulting a healthcare provider regarding the use of over-the-counter pain relievers.


Q: Is it generally safe to drink alcohol while taking Manosil?

Regulatory documents recommend against the consumption of alcohol while taking Manosil. Alcohol is a central nervous system depressant and can significantly worsen common side effects of the medicine, such as drowsiness and fatigue.


Q: Is Manosil safe for use during pregnancy or breastfeeding?

Available data from official sources indicate that use during pregnancy is generally not expected to increase the chance of major birth defects. If used while breastfeeding, official product information recommends short-term use, and monitoring of the infant for possible side effects is advised.


Q: Will Manosil interfere with the effectiveness of birth control pills?

Official safety information states that Manosil can cause an increase in prolactin hormone levels (hyperprolactinemia), which may lead to irregular menstrual cycles. Separately, severe diarrhea, which is a common gastrointestinal side effect of Manosil, can potentially reduce the absorption and effectiveness of oral contraceptives.


Q: What is the significance of the FDA safety classification for Manosil?

The medicine carries a Black Box Warning from the FDA, which is the strictest safety warning. This specifically concerns the risk of developing Tardive Dyskinesia (TD), a serious, potentially irreversible movement disorder. This risk increases with the duration of treatment.


Q: Does Manosil need to be tapered off (slowly reduced) when stopping use? / What happens if I stop taking Manosil suddenly?

Official regulatory guidelines advise against abrupt discontinuation of the medicine due to the risk of neurological adverse effects or the experience of withdrawal-like symptoms. If there is a decision to stop taking Manosil, it should be done in consultation with a healthcare provider to manage a gradual tapering schedule.


Q: If I miss a dose, what is the general recommendation for how soon to take the next one?

Regulatory documentation states that a double dose should not be taken to compensate for a missed one. To prevent drug accumulation and mitigate risk, a minimal interval of 6 hours between administrations must be strictly observed, regardless of whether a dose was missed.


Q: Is it true that Manosil works better if you take it with a meal?

For the oral formulation, official dosing instructions specify that the medicine should be taken on an empty stomach. The typical instruction is to take the tablets approximately 30 minutes before meals and at bedtime, as directed for optimal absorption.


Q: Can Manosil cause weight gain or loss?

While not classified as a very common side effect in the official prescribing information, there have been case reports documented in medical literature of patients experiencing unintended weight gain associated with the use of the active ingredient.


Q: Why do some doctors choose to prescribe Manosil over a similar drug?

Prescribing decisions are based on the patient's specific needs. The drug is officially classified to act as both a Dopamine D2 Antagonist (to reduce nausea) and a Prokinetic Agent (to stimulate gut movement). This dual action is a primary consideration in prescribing decisions.


Q: Is Manosil known to cause allergic reactions?

Yes, the official safety profile includes warnings about hypersensitivity. Severe reactions, including serious allergic reactions such as rash, hives, and swelling of the face, lips, or throat, are listed among the possible serious side effects.


Q: Is Manosil a controlled substance?

No, the active ingredient in Manosil is designated as a non-controlled substance by the U.S. Drug Enforcement Administration (DEA).


Q: Is it true that people with diabetes should be cautious when taking Manosil?

Yes, official safety information specifically notes that individuals with diabetes should be monitored closely. Regulatory documents indicate that the risk of developing the serious neurological side effect, Tardive Dyskinesia (TD), is explicitly documented to be increased in patients with diabetes mellitus.

How should Manosil be stored and disposed of?

Storage and Disposal Requirements for Manosil

Manosil (Metoclopramide) must be stored under specific environmental and container conditions as defined in official regulatory documents to maintain its stability.

Mandatory Storage Conditions

  • Temperature: Store at Controlled Room Temperature, between 20°C and 25°C (68°F and 77°F). Avoid excess heat, and the oral solution must be kept from freezing.
  • Protection: The medicine must be protected from light and stored away from excess moisture. Keep the container tightly closed and in its original packaging when applicable.
  • Child Safety: All forms must be stored out of the reach of children.

Handling and Disposal

Injection vials are single-dose; any unused portion must be discarded immediately. Solutions should be visually inspected and discarded if discoloration or particles are present. Disposal of expired or unused medication should be performed through a drug take-back program or by following specific household trash methods as outlined in official guidelines, and the medicine must not be flushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Manosil found in:

A-Z Index: